pharma news today glp-1 obesity drugs today Market Size to Hit USD 132.79 Bn by 2035 glp-1 obesity drug supply news

Tirzepatide is the first combination of entero-pancreatic hormones [dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RA] that has been approved for T2D management based on the findings from the phase 3 SURPASS programme

In April 2025 Pfizer was forced to discontinue a clinical trial with one of its experimental GLP-1 medicines to treat obesity due to potential drug induced liver injury found in one of the participants

By excluding them from the study, Sodhi said, they were able to tease out more carefully what might be linked to the drug versus the disease

While it may be tempting to buy apps once and install them onto a website, this can be unwise

Phentermine is one of the most affordable prescription weight loss medications available